# University of Groningen

## Prioritization of COPD protein biomarkers, based on a systematic study of the literature

Ongay Camacho, Sara; Klont, Frank; Horvatovich, Peter; Bischoff, Rainer; ten Hacken, Nick H.T.

[Link to publication in University of Groningen/UMCG research database](#)

# Prioritization of COPD protein biomarkers, based on a systematic study of the literature

**Sara Ongay[1], Frank Klont[2], Peter Horvatovich[2], Rainer Bischoff[2] and Nick H.T. ten Hacken[1]***

[1] University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
[2] University of Groningen, Department of Pharmacy, Analytical Biochemistry, 9713 AV, Groningen, The Netherlands

**Abstract**: Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease mostly due to smoking and until now diagnosed by spirometry (post bronchodilator $FEV_1$/FVC <70%). However, in spite of the usefulness of $FEV_1$ as diagnostic and prognostic tool, it has proven to be a weak indicator of future exacerbations, unable to predict lung function decline within COPD patients, as well as unable to identify the smokers "susceptible" to developing COPD at an early stage. Thus, there is an urgent need for biomarkers that address these questions and support clinical decision making in the diagnosis and treatment of (early) COPD. In this respect, considerable efforts have been devoted to identifying protein biomarkers that enable a better understanding of this complex disease and leading to better diagnostic and prognostic tools. However, in spite of the wide range of candidates that have been suggested as potentially useful COPD biomarkers, most remained at the level of the initial discovery, and only fibrinogen has been approved by the Food and Drug Administration (FDA) as predictor for all-cause mortality and COPD exacerbations. There is thus a need for future investigations of these biomarkers in large-scale and well characterized studies in order to prove their usefulness as surrogate endpoints. Based on this, the aim of the present review is to advance COPD biomarker development by providing a comprehensive overview of protein biomarker candidates which have been evaluated in clinical studies and prioritize them according to their potential of becoming valid, clinically useful COPD biomarkers.

**Keywords**: COPD, biomarker, surrogate marker, review

*Correspondence to: Nick ten Hacken, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands; Email: n.h.t.ten.hacken@umcg.nl

## Introduction

Chronic obstructive pulmonary disease (COPD) is defined as a 'common preventable and treatable disease that is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases'[1]. COPD is an umbrella term that covers several pathological conditions and has many clinical and pathological phenotypes[2]. Examples of such phenotypes are chronic bronchitis, emphysema, chronic mucus hypersecretion and small airways thickening. Besides encompassing pulmonary components, this term also covers additional features such as exacerbations and comorbidities, since COPD is recognized as a complex and multicomponent syndrome with both pulmonary and extrapulmonary manifestations[1,3–5]. The forced expiratory volume in 1 second ($FEV_1$) is the current "gold standard" marker of disease progression, response to therapy, and prediction of mortality[6]. Unfortunately, it has proven to be a weak indicator of future exacerbations, unable to predict lung function decline as well as ineffective for

developing treatment regimens that can significantly reduce mortality rates or alter the disease course[2,7]. For this reason, there has been a growing interest in discovering new biomarkers that would allow a better understanding of this heterogeneous and complex disease[4,8,9]. Interesting challenges in current COPD medicine include developing tools that allow optimizing therapeutic interventions following the shift of a general COPD treatment towards a more personalized, patient-centered medicine[10,11]. For example, biomarkers that would support decisions such as the use of bronchodilators and/or inhaled corticosteroids[12–14], are of outmost interest in order to select the most adequate treatment option for each patient[11]. Furthermore, the prediction of lung function decline amongst COPD patients and therefore development of biomarkers that enable differentiation of slow and fast decliners, would be of importance in developing early stage treatments for particularly the fast decliners as well as in understanding the mechanisms that are involved in the progression and severity of COPD[15–19]. In this respect, it is important to mention that only a small proportion (20–30%) of smokers develop COPD, suggesting that susceptibility to develop the disease is due to the interaction between genetic and environmental factors such as air pollution[20,21]. Being able to recognize individuals at high risk to develop COPD would help clinicians convincing healthy-smokers to quit smoking as well as understanding the genetic basis of the disease.

In COPD, the search for circulating blood biomarkers has mainly focused on plasma/serum proteins which are known to be involved in the systemic inflammatory response to smoking and subsequent lung injury repair[8,15–17,22–26]. In general, cytokines, chemokines, metalloproteases (e.g. MMP-9) and highly abundant acute phase reactants (e.g., C-reactive protein, fibrinogen) have been measured and found to differentiate COPD patients from healthy controls. This directed approach, however, suffers from the fact that proteins not previously suspected to be involved in the disease are not investigated. As a result, several unbiased proteomic studies of plasma and other biological fluids such as induced sputum, exhaled breath condensate, bronchoalveolar lavage or epithelial lining fluid, have been performed in order to find novel protein biomarkers differently expressed in COPD and healthy individuals[9,18,20,23]. While many potential biomarkers candidates have been pointed out, most of them remain at the level of their initial discovery,

while only few of them reached the level of clinical validation. In fact, this "biomarker gap" has considerably increased due to the application of proteomic strategies measuring thousands of proteins in groups of samples with 5–20 patients/controls per group. Considering that COPD is a complex and heterogeneous disease, it is unlikely that a single biomarker will be sufficient for COPD diagnosis, prognosis or treatment evaluation. Therefore, Devanarayan *et al.* stated that proteomic strategies should focus on delivering panels of biomarkers which enable the characterization of the different COPD phenotypes as well as reflecting underlying pathological pathways and comorbidities[15]. In line, Agusti *et al.* described a systemic inflammatory network pattern (called inflammome) in subgroups of COPD patients associated with different all-cause mortality and exacerbation frequency[27].

Taking all these into consideration, the aim of the present review is to advance biomarker development in COPD by providing a comprehensive overview of protein biomarker candidates which have been evaluated in large clinical studies, and have the potential of becoming valid and clinically useful biomarkers in the near future.

## Methodology and Results

Our search strategy started with the identification of those cohorts with more than 500 subjects and in which biological samples have been collected. For this search, we employed four complementary databases: PubMed, Cochrane Central Register of Controlled Trials, Biomarkers Module from the Thompson Reuters Integrity$^{SM}$ database and ClinicalTrials.gov. The search strategies followed in each case are summarized in Table 1. In all cases, resulting hits were screened, exclusion criteria applied and relevant hits selected. Exclusion criteria were: cohorts with less than 500 subjects; published only as a congress abstract; cohorts without biological samples collected; reviews or literature text-mining publications; studies not focusing on COPD but on dyspnea, bronchiectasis, asthma, or interstitial lung diseases. Based on these criteria we identified 72 cohorts. 52 hits were excluded because genomic or non-protein biomarkers (e.g. desmosine, vitamin D) were investigated, because hits did not have published results yet, or due to double hits in the four different databases. In this way 20 relevant cohorts remained (Table 2). Subsequently, we used PubMed to search for publications reporting protein biomarkers from these cohorts, using the

**Table 1.** Search strategy for COPD cohorts (>500 subjects, biological samples collected)

| Database | Search rules |
|---|---|
| PubMed | copd[Title] AND cohort [all fields] |
| Cochrane Central Register of Controlled Trials | #1  copd and biomarker<br>#2  copd and protein<br>#3  copd and serum<br>#4  copd and plasma<br>#5  copd and sputum<br>#6  copd and urine<br>#7  copd and bal<br>#8  copd and elf<br>#9  {or #1–#8} |
| Thompson Reuters Integrity[SM] Biomarkers Module | Indication type: COPD<br>Validity: late studies in humans (>500 subjects)<br>Type: proteomic<br>Substrate: DNA exclusion |
| ClinicalTrials.gov | Search term: COPD<br>Results filtered:<br>  -  Trials >500 subjects enrolled<br>  -  observational studies |

cohort name or the registration number. From those publications 39 proteins were identified that may have the potential to be relevant biomarkers in COPD (Table 3). Following proposed criteria of Sin *et al.*[2] for developing novel biomarkers in COPD this list was further reduced by selecting only those proteins which showed statistically significant differences between COPD patients and healthy smokers (Table 4). Afterwards this list of 7 prioritized proteins was examined according the other proposed criteria[2] demonstrating: biological plausibility in terms of a role in the pathogenesis of COPD, association with clinical outcomes, evidence that interventions modify the biomarker candidate, and evidence that these changes associate with important clinical outcomes.

## COPD Cohorts

Among the identified cohorts (Table 2), a number were observational such as the Bergen COPD study[28,29], PROMISE-COPD[30], the BODE study[31], the MESA Lung study[32] or ECLIPSE[33]. These studies have different aims covering a wide range of aspects related to COPD. PROMISE-COPD aims to investigate whether circulating biomarkers might be able to predict exacerbations during the stable phase of the disease and the clinical outcome of exacerbations in patients with COPD[30]. The BODE study investigated the hypothesis that a multidimensional index (the BODE index) allows a better categorization and prediction of disease outcome (mortality) than $FEV_1$ alone[31]. The MESA Lung Study is an ancillary study of the Mul-

ti-Ethnic Study of Atherosclerosis (MESA) with the aim of testing the chronic endothelial injury hypothesis of COPD and emphysema, in addition to examining subclinical cardiopulmonary interactions[32]. ECLIPSE is a 3-year longitudinal study with four specific aims: (i) definition of clinically relevant COPD subtypes, (ii) identification of parameters that predict disease progression in these subtypes, (iii) examination of biomarkers that correlate with COPD subtypes and may predict disease progression, and (iv) identification of novel genetic factors and/or biomarkers that both correlate with clinically relevant COPD subtypes and predict disease progression[33]. Furthermore, our systematic search identified interventional case-control studies in which different COPD treatments (neutrophil elastase inhibitors, long acting beta agonists, prophylactic antibiotic treatments, cholesterol lowering medication, or corticoidsteroids) were evaluated (NCT-00949975[34], NCT01110200[35], NCT00132860[36,37], NCT01061671[38], NCT00325897[39], EUROSCOP[40]). In this category, the Lung Health Study (LHS) is a representative example. The objectives of LHS I and III were (a) to determine whether an intervention program incorporating smoking cessation and the use of inhaled ipratropium bromide could slow down the decline of lung function and reduce the incidence of pulmonary morbidity over a 5-year period of follow-up in persons at high risk for developing COPD, and (b) to estimate the effects on lung function due to bronchodilators over and above the effects of smoking intervention[41]. In LHS II the effect of inhaled corticosteroids (triamcinolone) on the annual age-related decline in pulmonary function in patients with COPD was investigated[42].

Furthermore, we identified and selected cohorts with focus on different lung diseases in which a representative number of COPD patients were recruited. These cohorts are the SAPALDIA study and the European Community Respiratory Health Survey (ECRHS). SAPALDIA was designed to investigate the health effects from long-term exposure to air pollution[43] with the aim of assessing the prevalence of bronchial asthma, chronic (obstructive) bronchitis and allergic conditions in the adult population of Switzerland. An additional aim was the identification of potentially influencing factors, which could be personal (smoking, allergy status, family history, occupation) or environmental (outdoor and indoor pollution, aeroallergens, climate)[44]. The ECRHS aimed to estimate the variation in prevalence of asthma, exposure to risk factors

**Table 2.** Cohorts identified as relevant for COPD

| | Name | Abbreviation | Registration number |
|---|---|---|---|
| 1 | Bergen COPD cohort study | – | n.a. |
| 2 | Predicting Outcome using systemic Markers In Severe Exacerbations of COPD | PROMISE-COPD | ISRCTN99586989 |
| 3 | Evaluation of COPD to Longitudinally Identify Predictive Surrogate Endpoints | ECLIPSE | NCT00292552 |
| 4 | The longitudinal study BODE cohort of COPD patients | – | n.a. |
| 5 | Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA | MESA-Lung | NCT00843271 |
| 6 | Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With COPD on Treatment With Tiotropium | – | NCT00949975 |
| 7 | COPD Disease Post-hospitalization Study | – | NCT01110200 |
| 8 | Prophylactic Antibiotic Treatment of Patients With COPD | – | NCT00132860 |
| 9 | Simvastatin Therapy for Moderate and Severe COPD | STATCOPE | NCT01061671 |
| 10 | Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With COPD | MACRO study | NCT00325897 |
| 11 | European respiratory society study on chronic obstructive pulmonary disease | EUROSCOP | n.a. |
| 12 | Lung Health Study (I and III) | LHS I-III, II | NCT00000569/568 |
| 13 | Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults | SAPALDIA | n.a. |
| 14 | The European community respiratory health survey | ECRHS | n.a. |
| 15 | Atherosclerosis Risk in Communities Study | ARIC study | n.a. |
| 16 | The Malmo preventive project | – | n.a. |
| 17 | The Copenhagen cohorts (Copenhagen City Heart Study and the Copenhagen General Population Study) | – | n.a. |
| 18 | Cohort of outpatients from West China Hospital of Sichuan University | – | n.a. |
| 19 | The Rotterdam study | – | n.a. |
| 20 | National Health and Nutrition Examination Survey | NAHNES III | n.a. |

for asthma, and asthma treatment across 25 countries from the European Community[45,46]. It is known that COPD can have significant overlap with other lung-related diseases such as asthma[47], making these cohorts useful to investigate the performance of COPD biomarkers in populations with overlapping syndromes. In this line, cardiovascular disease is a well-known COPD co-morbidity which can influence patient mortality and hospitalization rates[48]. Thus, there have been different studies in which protein biomarkers have been investigated in subgroups of COPD patients from cardiovascular disease related cohorts. Examples of this are the ARIC study, a prospective study to investigate the etiology of atherosclerosis and its clinical sequelae and variation in cardiovascular risk factors, medical care, and disease by race, sex, place, and time[49]; the Malmö Prevention Project, a preventive case-finding program for cardiovascular risk factors and alcohol abuse in the city of Malmö[50]; or the Copenhagen City Heart Study[51], a prospective cohort study of individuals aged 20 years and older that were randomly selected from the population of Copenhagen.

Finally, general population cohorts with a relevant (>500) number of COPD subjects were identified and selected including the Copenhagen General Population Study[52], the Rotterdam study (prospective cohort study targeting cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, oncological, and respiratory diseases[53–55]), the National Health and Nutrition Examination Survey (cross-sectional survey providing an estimation of health and nutrition status among a representative group of civilian, noninstitutionalized US residents)[56,57] and the Cohort of outpatients from the West China Hospital of Sichuan University[58].

## COPD Protein Biomarkers

After the identification of relevant cohorts, we searched for all publications from these cohorts in which proteins had been investigated or evaluated as potential COPD biomarkers (see Table 3 for the list of proteins). All the proteins on this list have been shown or suggested to be linked to the pathogenesis of the disease, an important *criterium* in the selection of useful biomarkers in COPD[2]. Indeed this list reflects the

complexity of the underlying pathogenesis of COPD, involving inflammation, oxidative stress (e.g., due to smoking), the protease/anti-protease imbalance, environmental factors (such as exposure to pollutants or internal cooking), and genetic predispositions[5,59]. Accumulating evidence indicates that chronic inflammatory and immune responses play key roles in the development and progression of COPD[60,61]. In this respect, most of the potential biomarkers included in our list are proteins involved in inflammation or the immune response such as CRP, IL-6, beta defensin 2, among many others[25–27,29,36,37,54,62–74]. One of the main causes leading to COPD is chronic smoking which exposes the respiratory tract to reactive oxygen species, resulting in oxidative stress and injury (which in the last instance leads also to inflammation)[59,75]. Thus, biomarkers of oxidative stress such as cerulo-plasmin[68] could be used to reflect this characteristic of COPD. Furthermore, one of the main components of COPD is emphysema which is caused by an imbalance between proteases and anti-proteases resulting in lung parenchymal destruction. Representative molecules of this process are MMP's[66,72] involved in the breakdown of the extracellular matrix and in tissue remodeling, as well as, VEGF involved in angiogenesis and tissue remodeling[72]. Furthermore, our protein list comprises lung-specific proteins such as SPD and CC-16[76–79]. CC-16 is secreted by non-ciliated club cells (formerly known as Clara cells) which are mainly present in the respiratory bronchioles and by non-ciliated columnar cells present in the small airways. SPD is found in the endoplasmic reticulum of type II pneumocytes and in the secretory granules of club cells. SPD plays a role in the protection against viral infections, the clearance of bacteria, fungi and apoptotic cells, as well as in inflammation[80]. Finally, proteins that enable to investigate the effect of long-term inhaled corticosteroid therapy on bone mineral density (a clinical feature in COPD) such as osteocalcin were identified[81,82].

**Table 3.** Proteins investigated as potential COPD biomarkers within relevant COPD cohorts

| Protein name | Abbreviation | ID | Proposed pathophysiological role | Reference |
|---|---|---|---|---|
| Adiponectin | | Q15848 | Anti-inflammatory, anti-diabetic, and anti-atherogenic activities | [64,66,105] |
| Beta-defensin-2 | | A4H1Z7 | Role in pulmonary immunity | [66] |
| Calprotectin | | P05109 | Anti-infective and anti-inflammatory activities | [36] |
| Chitinase3-like-1 | YKL-40 | P36222 | Role in cell proliferation and differentiation , inflammation, extracellular tissue remodeling, and protection against apoptosis | [37] |
| Club cell protein 16 | CC-16 | P11684 | Pulmonary inflammatory protein | [22,26,35,78,79,86,91,106,107] |
| C-C motif chemokine 18 | PARC/CCL-18 | P55774 | Lung-predominant inflammatory protein. | [66,70,72,73,86–88,91,107,108] |
| C-C motif chemokine 2 | CCL2 | P13500 | Inflammatory chemokine | [66] |
| C-X-C motif chemokine 16 | CXCL 16 | Q9H2A7 | Inflammatory chemokine | [29] |
| Ceruloplasmin | | P00450 | Protein involved in oxidative stress | [68] |
| C-reactive protein | CRP | P02741 | Secreted by the liver in response to a variety of inflammatory cytokines | [22,26,27,29,34,38,52,58,64,66, 69,70,84,86–91,93–95,106–115] |
| C-X-C motif chemokine 10 | CXCL-10 | P02778 | Inflammatory chemokine | [66] |
| E-selectin | | P16581 | Cell adhesion molecule expressed only on endothelial cells activated by cytokines. | [62] |
| Fibrinogen | | Q08830, P02671, P02675 | Coagulation factor | [22,26,27,64,66,68,70,83–91,106 –108,111,114,116] |
| Fibronectin to CRP ratio | | - | Coagulation factor/ secreted by the liver in response to a variety of inflammatory cytokines | [69] |
| Haptoglobin | | P00738 | Inflammatory role | [68] |
| Hepatocyte growth factor | | P14210 | Systemic inflammation marker | [66] |
| Interleukin-1 beta | IL 1β | P01584 | Proinflammatory cytokine | [67] |
| Interleukin-6 | IL 6 | P05231 | Inflammatory interleukin | [22,26 27,34,58,64,66,67,70,72,84,86,9 1,95,107,111,114,115] |
| Interleukin-8 | IL 8 | P10145 | Inflammatory interleukin | [22,26,27,34,66,70,72,84,86,91, 107,115] |

Continued 3

| Protein name | Abbreviation | ID | Proposed pathophysiological role | Reference |
|---|---|---|---|---|
| Interleukin-12 subunit beta | IL-12β | P29460 | Inflammatory interleukin | [66] |
| Pro-interleukin-16 | IL 16 | Q14005 | Inflammatory interleukin | [72] |
| Leptin | | P41159 | Role in lung maturation and development | [64] |
| Leukotriene A-4 hydrolase | | P09960 | Inflammatory marker | [74] |
| Mannose binding lectin | MBL | P11226 | Collectin involved in host defense against infection | [63,117] |
| Neutrophil collagenase | MMP-8 | P22894 | Breakdown of extracellular matrix involved in tissue remodeling | [66] |
| Matrix metalloproteinase-9 | MMP-9 | P14780 | Breakdown of extracellular matrix involved in tissue remodeling | [66,72] |
| Monocyte chemoattractant protein | MCP-1/CCL2 | P13500 | Chemokine regulating migration and infiltration of monocytes/macrophages | [72,112] |
| Myeloperoxidase | MPO | P05164 | Cytotoxic protein used by neutrophils to kill bacteria and other pathogens | [66,71] |
| Neutrophil gelatinase associated lipocalin | NGAL | P80188 | Inhibition of bacterial growth and enhancement of matrix degradation | [113,118] |
| Orosomucoid | AGP1 | P02763 | Inflammatory marker | [68] |
| Osteocalcin | | P02818 | Indicator of bone mineral density | [81,82] |
| Osteoprotegrin/Tumor necrosis factor receptor superfamily member 11B | OPG | O00300 | Is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) | [52,54,119] |
| soluble intercellular adhesion molecule | ICAM-1 | P05362 | Facilitates leukocyte adhesion and migration across the endothelium | [62] |
| Soluble receptor for advanced glycation endproducts | sRAGE | Q15109 | The RAGE pathway has been shown to be associated with several inflammatory diseases | [65,91] |
| Soluble tumor necrosis factor receptor 1 | sTNF-R1 | P19438 | Proinflammatory cytokine | [52,54,119] |
| Surfactant protein D | SPD | P35247 | Pulmonary protein involved in innate immunity | [22,26,35,70,76,77,80,86,87,91, 106–108,115] |
| Tumor necrosis factor | TNFα | P01375 | Proinflammatory cytokine | [22,26,27,34,58,67,70,72,84,86, 91,107] |
| Vascular endothelial growth factor | VEGF | P15692 | Angiogenic protein/marker of injury and repair | [72] |
| Vitamin D binding protein | DBP | Q6LDC6 | It binds to vitamin D and its plasma metabolites and transports them to target tissues | [106] |

## Prioritized COPD Protein Biomarkers

The list of potential protein biomarkers (Table 3) was further reduced by selecting only those that show statistically significant differences between COPD patients and healthy smokers (Table 4). This follows the recommendation to demonstrate a strong, consistent and independent association between a biomarker and COPD[2]. In this way, 7 potential proteins remained: fibrinogen, CRP, IL-6, PARC, SPD, CC-16, and sRAGE.

Among these proteins, fibrinogen was recently approved as biomarker for all-cause mortality and exacerbations in COPD subjects. Fibrinogen reflects the systemic inflammatory component of COPD, is elevated in COPD patients[27,64,66,83–85], and associated with the severity of the disease[27] and FEV$_1$[26]. Furthermore, fibrinogen is associated with increased exacerbation frequency, hospitalization, and mortality in COPD patients[66,68,83,86–88], as well as with increased cardiovascular events[70,89–91]. Therefore, fibrinogen has been accepted by the FDA and COPD Biomarker Qualification Consortium (CBQC) for the stratification of subjects at risk for hospitalization and mortality[92]. CRP and IL-6 have also been discussed within the CBQC as interesting COPD biomarkers since they share many of the features of fibrinogen. CRP and IL-6 also reflect the systemic inflammatory component of COPD, are increased in COPD patients and are associated with important clinical outcomes[27,29,52,64,66,70,84,86–90,93–95]. However, the biological variability of fibrinogen was lower than for IL-6 or CRP, which both display a wide variability in stable COPD subjects[66,92].

The proteins SPD, CC-16 and PARC are promising COPD biomarkers, particularly because they are

**Table 4.** Prioritized proteins able to discriminate between COPD patients and healthy smokers

| Protein name | Abbreviation | Protein ID | Sample | Concentration in smoker controls | Concentration in COPD patients | Significance (p-value) | Reference |
|---|---|---|---|---|---|---|---|
| Club cell protein 16 | CC-16 | P11684 | serum | 5.6 (3.1) ng/ml | 4.9 (3.4) ng/ml | <0.001 | [78] |
| C-C motif chemokine 18 | PARC/CCL-18 | P55774 | serum | 81 (21) ng/ml | 105 (26) ng/ml | <0.0001 | [73] |
| C-reactive protein | CRP | P02741 | serum | 1.6 (0.8–3.3) µg/ml | 3.2 (1.5–7.1) µg/ml | <0.001 | [27] |
| Fibrinogen | | Q08830, P02671, P02675 | EDTA plasma | 391 (348–436) mg/dl | 448 (388–517) mg/dl | <0.001 | [27] |
| Interleukin-6 | IL 6 | P05231 | serum | 0.6 (0.3–1.3) pg/ml | 1.5 (0.8–3.1) pg/ml | <0.001 | [27] |
| Soluble receptor for advanced lycation endproducts | sRAGE | Q15109 | serum | 1.7 (0.7) ng/ml | 1.4 (0.6) ng/ml | <0.001 | [65] |
| Surfactant protein D | SPD | P35247 | Serum | 114(76–162) ng/ml | 121 (85–174) ng/ml | 0.021 | [80] |

Concentrations are presened as mean (standard deviation) or median (interquartile range).

highly lung specific. PARC was shown to be elevated in COPD patients when compared to healthy smoking controls[66,73], and an association between the levels of PARC and body mass index, FEV$_1$, BODE index, and exacerbation rate was observed[24]. However, in later work only a statistically relevant association with the BODE index was reconfirmed[72]. Furthermore, elevated blood PARC levels have been associated with a higher risk of mortality and exacerbation episodes in COPD patients[86–88]. The largest study of PARC in COPD to date is the one performed by Sin and co-workers[73]. They observed that a 2-week treatment with prednisolone associated with reduced PARC levels when compared to placebo. Furthermore, a relationship of PARC concentrations with a future risk of cardiovascular hospitalization and mortality and with total mortality was observed. However, some of the results of this study were contradictory: in the LHS study higher PARC levels were associated with lower baseline FEV$_1$ values and increased mortality due to cardiovascular disease, while in the ECLIPSE subjects the association with FEV$_1$ could not be replicated. Finally, PARC levels show wide variability over time both in stable COPD patients and healthy controls[66]. Thus, additional work is needed to determine the utility of this protein as COPD biomarker.

Amongst the lung specific proteins, SPD and CC-16 have proven to be more stable over time than PARC which could make them more useful COPD biomarkers[66]. SPD is mainly produced in type II pneumocytes[96,97] and plays an important role in pulmonary immune defense[98], making it an interesting potential biomarker in COPD. In this respect, polymorphisms in the surfactant protein–D gene (SFTPD) have been shown to be associated with susceptibility to develop COPD and to influence serum concentra-

tions of SPD[22,77]. Furthermore, SPD levels were found to be elevated in COPD patients when compared to healthy smoking controls, although no association with COPD severity[80] nor with the rate of change in FEV$_1$[26] was observed. SPD has also proven to be associated with a higher risk for exacerbations[80,87] and mortality[86] as well as being reduced after prednisolone treatment[80]. SPD has different isoforms including a nitrosylated and a cleaved form[76], however, these modified SPD products associate worse with clinical outcomes of COPD than non-modified SPD. Although considered a promising COPD biomarker, SPD has so far not proven to be a reliable prognostic tool requiring further validation of the findings observed so far. CC-16 is predominantly secreted from non-ciliated club cells and is localized in terminal and respiratory bronchial epithelia[99]. Significant associations between several single nucleotide polymorphisms and circulating levels of CC-16 have been identified in genome-wide association studies, however, no strong associations between genotypic variations, circulating CC16 levels and risk for developing COPD were observed[22]. CC-16 is decreased in COPD patients when compared to healthy smoking controls[78] and has been significantly and independently associated with the rate of change in FEV$_1$[26]. However, CC-16 levels were not significantly associated with mortality[86]. Furthermore, changes in CC-16 levels are not specific to one agent, disease state or specific exposure[100]. As CC-16 is likely to be affected by other forms of lung disease the biomarker role of CC-16 in COPD is uncertain and additional data is required to assess more rigorously its potential as surrogate for disease phenotype, severity and/or progression.

sRAGE, the soluble form of the receptor of ad-

vanced glycation end-products (RAGE), and a multi-ligand member of the immunoglobulin superfamily of cell surface molecules, has been associated with several diseases including diabetes mellitus, cardiovascular, and respiratory diseases[101–103]. RAGE is expressed in a variety of tissues including the lung. However, unlike in other tissues, RAGE is highly expressed in the lung under normal physiological conditions[101]. Increased expression of RAGE was demonstrated in the proximal and distal airways of COPD patients compared to both smoking and non-smoking controls, and these levels correlated positively with impaired lung function[104]. sRAGE is the resulting product of both alternative splicing (esRAGE) and cleavage of membrane-bound RAGE[101,102]. Circulating levels of sRAGE are decreased in COPD patients when compared to healthy smoking controls and appear to be associated with emphysema independently of COPD severity[65]. In addition to the association of sRAGE with emphysema, two SNPs in the gene coding for RAGE (AGER locus) were significantly associated with systemic sRAGE levels. These results indicate that sRAGE is a very promising COPD biomarker that deserves further investigation in order to prove its usefulness in COPD diagnosis, prognosis and treatment development.

It is worth mentioning that all of the described studies used ligand binding assays (LBAs; mainly ELISA), often from the same supplier, to quantify proteins in biological matrices. This bears the risk that forms of a given protein that are recognized by the antibody(ies) generate signals while others do not, meaning that our picture of how these biomarker candidates reflect disease development is likely incomplete. There is further a risk that systematic bias due to cross-reactivity of the antibodies with other proteins may affect the results. LBAs are generally not suitable to discriminate between different forms of a protein due to genetic variability (e.g., due to splicing, single amino acid variation, different allele distribution) or post-translational modifications (e.g. cleavage by proteases, modifications due to oxidative stress). Alternative methodologies based on chemical analysis principles such as LC-MS may provide a different, more detailed picture of protein heterogeneity with possibly better sensitivity and specificity and predictive values for the various aspects of COPD.

## Conclusion

While many protein biomarker candidates have been

suggested for COPD diagnosis and prognosis, so far only fibrinogen has been approved by the FDA for some aspects of the disease. Validation of promising biomarkers (for example those in Table 4) in well-designed studies, taking into account the different phenotypes of COPD, is thus urgently needed to reduce the gap between initial discovery and clinical application. Most of the studies performed so far comprise observational cohort and small-sized experimental studies, while large randomized clinical trials (e.g. evaluating changes in biomarkers in relation to interventions and clinical outcome) are scarce. Most of the current biomarker candidates are not lung-specific but may reflect the systemic aspects of COPD and its associated co-morbidities. There is a need for lung-specific biomarkers derived from proteins that are either only expressed in the lung (CC-16, SPD), or highly over-represented in the lung (RAGE). Because of the complexity of COPD, it is not likely that a single biomarker will be able to address the different aspects (phenotypes) of the disease. In this respect, a panel of biomarkers may be needed to guide personalized treatments of COPD patients[27].

## Conflict of Interest and Funding

## References

1. Vestbo J, 2014, COPD: definition and phenotypes. *Clinics in chest medicine*, vol.35(1): 1–6.

2. Sin D D and Vestbo J Ã, 2009, Biomarkers in chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, vol.6(6): 543–545.

3. Han M K, Agusti A, Calverley P M, *et al.* 2010, Chronic obstructive pulmonary disease phenotypes: the future of COPD. *American Journal of Respiratory and Critical Care Medicine*, vol.182(5): 598–604.

4. MacNee W, 2013, Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. *Annals of Medicine*, vol.45(3): 291–300.

5. Stockley R A, 2014, Biomarkers in chronic obstructive pulmonary disease: Confusing or useful? *International Journal of COPD*, vol.9: 163–177.

6. Kristan S S, 2013, Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice? *Archivum Immunologiae et Therapiae Experimentalis*,

vol.61(6): 469–481.

7. Russell R E, 2014, Chronic obstructive pulmonary disease: getting it right. Does optimal management of chronic obstructive pulmonary disease alter disease progression and improve survival? *Current opinion in pulmonary medicine*, vol.20(2): 127–131.

8. Faner R, Tal-Singer R, Riley J H, *et al.* 2014, Lessons from ECLIPSE: a review of COPD biomarkers. *Thorax*, vol.69(7): 666–672.

9. Pelaia G, Terracciano R, Vatrella A, *et al.* 2014, Application of proteomics and peptidomics to COPD. *Biomed Research International*, vol.2014(2014): 764581.

10. Agusti A and MacNee W, 2013, The COPD control panel: towards personalised medicine in COPD. *Thorax*, vol.68(7): 687–690.

11. Luis Lopez-Campos J, Bustamante V, Munoz X, *et al.* 2014, Moving towards patient-centered medicine for copd management: multidimensional approaches versus phenotype-based medicine — a critical view. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.11(5): 591–602.

12. Gershon A S, Campitelli M A, Croxford R, *et al.* 2014, Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. *Jama—Journal of the American Medical Association*, vol.312(11): 1114–1121.

13. Vestbo J, Vogelmeier C, Small M, *et al.* 2014, Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. *Respiratory medicine*, vol.108(5): 729–736.

14. Yang I A, Clarke M S, Sim E H A, *et al.* 2012, Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, (7): CD002991–CD002991.

15. Devanarayan V, Scholand M-B, Hoidal J, *et al.* 2010, Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.7(1): 51–58.

16. Higashimoto Y, Iwata T, Okada M, *et al.* 2009, Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. *Respiratory medicine*, vol.103(8): 1231–1238.

17. Holz O, Waschki B, Roepcke S, *et al.* 2014, Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD. *Bmc Pulmonary Medicine*, vol.14: 30.

18. Rana G S J B, York T P, Edmiston J S, *et al.* 2010, Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette sm-okers with chronic obstructive pulmonary disease (COPD). *Analytical and Bioanalytical Chemistry*, vol.397(5): 1809–1819.

19. Tashkin D P, 2013, Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. *Current opinion in pulmonary medicine*, vol.19(2): 116–124.

20. 20. Franciosi L, Postma D S, Van den Berge M, *et al.* 2014, Susceptibility to COPD: differential proteomic profiling after acute smoking. *PloS one*, vol.9(7): e102037.

21. Tzortzaki E G, Tsoumakidou M, Makris D, *et al.* 2006, Laboratory markers for COPD in "susceptible" smokers. *Clinica Chimica Acta*, vol.364(1–2): 124–138.

22. Kim D K, Cho M H, Hersh C P, *et al.* 2012, Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.186(12): 1238–1247.

23. Merali S, Barrero C A, Bowler R P, *et al.* 2014, Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.11(2): 177–189.

24. Pinto-Plata V, Toso J, Lee K, *et al.* 2007, Profiling serum biomarkers in patients with COPD: associations with clinical parameters. *Thorax*, vol.62(7): 595–601.

25. Pinto-Plata V M, Mullerova H, Toso J F, *et al.* 2006, C-reactive protein in patients with COPD, control smokers and non-smokers. *Thorax*, vol.61(1): 23–28.

26. Vestbo J, Edwards L D, Scanlon P D, *et al.* 2011, Changes in forced expiratory volume in 1 second over time in COPD. *New England Journal of Medicine*, vol.365(13): 1184–1192.

27. Agusti A, Edwards L D, Rennard S I, *et al.* 2012, Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PloS one*, vol.7(5): e37483. 10.1371/journal.pone.0037483

28. Eagan T M L, Eide G E, Gulsvik A, *et al.* 2002, Nonresponse in a community cohort study — predictors and consequences for exposure-disease associations. *Journal of clinical epidemiology*, vol.55(8): 775–781.

29. Eagan T M L, Ueland T, Wagner P D, *et al.* 2010, Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. *European Respiratory Journal*, vol.35(3): 540–548.

30. Stolz D, Kostikas K, Blasi F, *et al.* 2014, Adreno-medullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. *European Respiratory Journal*, vol.43(2): 397–408.

31. Celli B R, Cote C G, Marin J M, *et al.* 2004, The body-mass index, airflow obstruction, dyspnea, and exercise

capacity index in chronic obstructive pulmonary disease. *New England Journal of Medicine*, vol.350(10): 1005–1012.

32. Hankinson J L, Kawut S M, Shahar E, *et al.* 2010, Performance of American Thoracic Society —recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. *Chest*, vol.137(1): 138–145.

33. Vestbo J, Anderson W, Coxson H O, *et al.* 2008, Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). *European Respiratory Journal*, vol.31(4): 869–873.

34. Vogelmeier C, Aquino T O, O'Brien C D, *et al.* 2012, A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.9(2): 111–120.

35. Ohar J A, Crater G D, Emmett A, *et al.* 2014, Fluticasone propionate/salmeterol 250/50 mu g versus salmeterol 50 mu g after chronic obstructive pulmonary disease exacerbation. *Respiratory Research*, vol.15: 105.

36. Holmgaard D B, Mygind L H, Titlestad I, *et al.* 2013, Calprotectin — a marker of mortality in COPD? Results from a prospective cohort study. *Copd—Journal of Chronic Obstructive Pulmonary Disease* vol.10(5): 581–587.

37. Holmgaard D B, Mygind L H, Titlestad I L, *et al.* 2013, Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. *Bmc Pulmonary Medicine*, vol.13: 77.

38. Criner G J, Connett J E, Aaron S D, *et al.* 2014, Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. *New England Journal of Medicine*, vol.370(23): 2201–2210.

39. Albert R K, 2012, Azithromycin for prevention of exacerbations of COPD (vol 365, pg 689, 2011). *New England Journal of Medicine*, vol.366(14): 1356.

40. Pauwels R A, Lofdahl C G, Laitinen L A, *et al.* 1999, Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. *New England Journal of Medicine*, vol.340(25): 1948–1953.

41. Connett J E, Kusek J W, Bailey W C, *et al.* 1993, Design of the lung health study — a randomized clinical- trial of early intervention for chronic obstructive pulmonary-disease. *Controlled Clinical Trials* vol.14(2): S3–S19.

42. Altose M D, Redline S, Deitz C D, *et al.* 2000, Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *New England Journal of Medicine*, vol.343(26): 1902–1909.

43. Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch N M, *et al.* 2005, Follow-up of the Swiss cohort study on air pollution and lung diseases in adults (SAPALDIA 2) 1991–2003: methods and characterization of participants. *Sozial-Und Praventivmedizin*, vol.50(4): 245–263.

44. Martin B W, Ackermann-Liebrich U, Leuenberger P, *et al.*, 1997, SAPALDIA: methods and participation in the cross-sectional part of the Swiss study on air pollution and lung diseases in adults. *Sozial-Und Praventivmedizin*, vol.42(2): 67–84.

45. Burney P G J, Luczynska C, Chinn S, *et al.* 1994, The European Community Respiratory Health Survey. *European Respiratory Journal*, vol.7(5): 954–960.

46. European Community Respiratory Health Survey II Steering Commitee, 2002, The European Community Respiratory Health Survey II. *European Respiratory Journal*, vol.20(5): 1071–1079.

47. Bujarski S, Parulekar A D, Sharafkhaneh A, *et al.* 2015, The asthma COPD overlap syndrome (ACOS). *Current Allergy and Asthma Reports*, vol.15(3): 509.

48. Buchan A, Bennett R, Coad A, *et al.* 2015, The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD. *Open Heart*, vol.2(1): e000052.

49. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. 1989, *American Journal of Epidemiology*, vol.129(4): 687–702.

50. Berglund G, Eriksson K F, Israelsson B, *et al.* 1996, Cardiovascular risk groups and mortality in an urban Swedish male population: The Malmo Preventive Project. *Journal of internal medicine*, vol.239(6): 489–497.

51. Schnohr P, Jensen G, Nyboe J, *et al.* 1977, [The Copenhagen City Heart Study. A prospective cardiovascular population study of 20,000 men and women]. *Ugeskrift for laeger*, vol.139(32): 1921–1923.

52. Dahl M, Vestbo J, Zacho J, *et al.* 2011, C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. *Thorax*, vol.66(3): 197–204.

53. Hofman A, Breteler M M B, van Duijn C M, *et al.* 2007, The Rotterdam Study: objectives and design update. *European journal of epidemiology*, vol.22(11): 819–829.

54. Hofman A, van Duijn C M, Franco O H, *et al.* 2011, The Rotterdam Study: 2012 objectives and design update. *European journal of epidemiology*, vol.26(8): 657–686.

55. van Durme Y M T A, Verhamme K M C, Stijnen T, *et al.* 2009, Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam Study. *Chest*, vol.135(2): 368–377.

56. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: pro-

grams and collection procedures. 1994, *Vital and Health Statistics. Series 1, Programs and Collection Procedures*, (32): 1–407.

57. Ezzati T M, Massey J T, Waksberg J*, et al.* 1992, Sample design: Third National Health and Nutrition Examination Survey. *Vital and health Statistics.Series 2, Data Evaluation and Methods Research*, (113): 1–35.

58. Liang B and Feng Y, 2012, The association of low bone mineral density with systemic inflammation in clinically stable COPD. *Endocrine*, vol.42(1): 190–195.

59. Fischer B M, Pavlisko E and Voynow J A, 2011, Pathogenic triad in COPD: oxidative stress, protease-anti-protease imbalance, and inflammation. *International Journal of Chronic Obstructive Pulmonary Disease*, vol.6: 413–421.

60. Rovina N, Koutsoukou A and Koulouris N G, 2013, Inflammation and immune response in COPD: where do we stand? *Mediators of inflammation*, vol.2013(2013): 413735.

61. Sethi S, Mahler D A, Marcus P*, et al.* 2012, Inflammation in COPD: implications for management. *American Journal of Medicine*, vol.125(12): 1162–1170.

62. Aaron C P, Schwartz J E, Bielinski S J*, et al.* 2015, Intercellular adhesion molecule 1 and progression of percent emphysema: the MESA Lung Study. *Respiratory medicine*, vol.109(2): 255–264.

63. Albert R K, Connett J, Curtis J L*, et al.* 2012, Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease. *International Journal of Chronic Obstructive Pulmonary Disease*, vol.7: 767–777.

64. Breyer M-K, Rutten E P A, Locantore N W*, et al.* 2012, Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. *European journal of clinical investigation*, vol.42(9): 983–991.

65. Cheng D T, Kim D K, Cockayne D A*, et al.* 2013, Systemic soluble receptor for advanced glycation end-products is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.188(8): 948–957.

66. Dickens J A, Miller B E, Edwards L D*, et al.* 2011, COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. *Respiratory Research*, vol.12: 146.

67. Eagan T M L, Gabazza E C, D'Alessandro-Gabazza C*, et al.* 2012, TNF-alpha is associated with loss of lean body mass only in already cachectic COPD patients. *Respiratory Research*, vol.13: 48.

68. Engstrom G, Segelstorm N, Ekberg-Aronsson M*, et al.*, 2009, Plasma markers of inflammation and incidence of

hospitalisations for COPD: results from a popula-tion-based cohort study. *Thorax*, vol.64(3): 211–215.

69. Man S F P, Xing L, Connett J E*, et al.* 2008, Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? *European Respiratory Journal*, vol.32(6): 1451–1457.

70. Miller J, Edwards L D, Agusti A*, et al.* 2013, Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respiratory Medicine*, vol.107(9): 1376–1384.

71. Park H Y, Man S F P, Tashkin D*, et al.* 2013, The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD). *PloS one*, vol.8(4): e61315.

72. Pinto-Plata V, Casanova C, Muellerova H*, et al.* 2012, Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. *Respiratory Research*, vol.13: 71.

73. Sin D D, Miller B E, Duvoix A*, et al.* 2011, Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.183(9): 1187–1192.

74. Wells J M, O'Reilly P J, Szul T*, et al.* 2014, An aberrant leukotriene A(4) hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.190(1): 51–61.

75. Fischer B M, Voynow J A and Ghio A J, 2015, COPD: balancing oxidants and antioxidants. *International Journal of Chronic Obstructive Pulmonary Disease*, vol.10: 261–76.

76. Duvoix A, Miranda E, Perez J*, et al.* 2011, Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.8(2): 79–95.

77. Foreman M G, Kong X, DeMeo D L*, et al.* 2011, Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. *American Journal of Respiratory Cell and Molecular Biology*, vol.44(3): 316–322.

78. Lomas D A, Silverman E K, Edwards L D*, et al.* 2008, Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. *Thorax*, vol.63(12): 1058–1063.

79. Park H Y, Churg A, Wright J L*, et al.* 2013, Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.188(12): 1413–1419.

80. Lomas D A, Silverman E K, Edwards L D*, et al.* 2009, Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. *European*

*Respiratory Journal*, vol.34(1): 95–102.

81. Johnell O, Pauwels R, Lofdahl C G, *et al.* 2002, Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler (R). *European Respiratory Journal*, vol.19(6): 1058–1063.

82. Scanlon P D, Connett J E, Wise R A, *et al.* 2004, Loss of bone density with inhaled triamcinolone in Lung Health Study II. *American Journal of Respiratory and Critical Care Medicine*, vol.170(12): 1302–1309.

83. Mannino D M, Valvi D, Mullerova H, *et al.* 2012, Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.9(4): 359–366.

84. Romme E A P M, Murchison J T, Edwards L D, *et al.* 2013, CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. *Journal of Bone and Mineral Research*, vol.28(6): 1369–1377.

85. Waschki B, Spruit M A, Watz H, *et al.* 2012, Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. *Respiratory medicine*, vol.106(4): 522–530.

86. Celli B R, Locantore N, Yates J, *et al.* 2012, Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.185(10): 1065–1072.

87. Hurst J R, Vestbo J, Anzueto A, *et al.* 2010, Susceptibility to exacerbation in chronic obstructive pulmonary disease. *New England Journal of Medicine*, vol.363(12): 1128–1138.

88. Mullerova H, Maselli D J, Locantore N, *et al.* 2015, Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. *Chest*, vol.147(4): 999–1007.

89. Parker D R, Liu J, Roberts M B, *et al.* 2014, Is inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. *Bmc Pulmonary Medicine*, vol.14: 195.

90. Thomsen M, Ingebrigtsen T S, Marott J L, *et al.* 2013, Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. *Jama—Journal of the American Medical Association*, vol.309(22): 2353–2361.

91. Williams M C, Murchison J T, Edwards L D, *et al.* 2014, Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. *Thorax*, vol.69(8): 718–723.

92. Casaburi R, Celli B, Crapo J, *et al.* 2013, The COPD Biomarker Qualification Consortium (CBQC). *Copd—Journal of Chronic Obstructive Pulmonary Disease*, vol.10(3): 367–377.

93. Lahousse L, Loth D W, Joos G F, *et al.* 2013, Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. *Pulmonary pharmacology & therapeutics*, vol.26(2): 212–217.

94. Man S F P, Connett J E, Anthonisen N R, *et al.* 2006, C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. *Thorax*, vol.61(10): 849–853.

95. van Durme Y M T A, Verhamme K M C, Aarnoudse A-J L H J, *et al.* 2009, C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.179(5): 375–382.

96. Madsen J, Kliem A, Tornoe I, *et al.* 2000, Localization of lung surfactant protein D on mucosal surfaces in human tissues. *Journal of Immunology*, vol.164(11): 5866–5870.

97. Voorhout W F, Veenendaal T, Kuroki Y, *et al.* 1992, Immunocytochemical localization of surfactant protein-D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. *Journal of Histochemistry & Cytochemistry*, vol.40(10): 1589–1597.

98. Crouch E and Wright J R, 2001, Surfactant proteins A and D and pulmonary host defense. *Annual Review of Physiology*, vol.63: 521–554.

99. Singh G, Singh J, Katyal S L, *et al.* 1988, Identification, cellular-localization, isolation, and characterization of human Clara cell-specific 10-Kd protein. *Journal of Histochemistry & Cytochemistry*, vol.36(1): 73–80.

100. Lakind J S, Holgate S T, Ownby D R, *et al.* 2007, A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. *Biomarkers*, vol.12(5): 445–467.

101. Buckley S T and Ehrhardt C, 2010, The receptor for advanced glycation end products (RAGE) and the lung. *Journal of Biomedicine and Biotechnology*, vol.2010: 917108.

102. Lindsey J B, Cipollone F, Abdullah S M, *et al.* 2009, Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. *Diabetes & Vascular Disease Research*, vol.6(1): 7–14.

103. Selvin E, Halushka M K, Rawlings A M, *et al.* 2013, sRAGE and risk of diabetes, cardiovascular disease, and death. *Diabetes*, vol.62(6): 2116–2121.

104. Ferhani N, Letuve S, Kozhich A, *et al.* 2010, Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, vol.181(9): 917–927.

105. Yoon H I, Li Y, Man S F P, *et al.* 2012, The complex relationship of serum adiponectin to COPD outcomes. *Chest*, vol.142(4): 893–899.

106. Berg I, Hanson C, Sayles H, *et al.* 2013, Vitamin D, vitamin D binding protein, lung function and structure in COPD. *Respiratory medicine*, vol.107(10): 1578–1588.

107. Hanania N A, Muellerova H, Locantore N W, *et al.* 2011, Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. *American Journal of Respiratory and Critical Care Medicine*, vol.183(5): 604–611.

108. Donaldson G C, Muellerova H, Locantore N, *et al.* 2013, Factors associated with change in exacerbation frequency in COPD. *Respiratory Research*, vol.14: 79–79.

109. Ólafsdóttir I S, Gíslason T, Thjóðleifsson B, *et al.* 2007, Gender differences in the association between C-reactive protein, lung function impairment, and COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, vol.2(4): 635.

110. Bridevaux P O, Gerbase M W, Schindler C, *et al.* 2009, Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2. *European Respiratory Journal*, vol.34(2): 332–339.

111. Diaz A A, Zhou L, Young T P, *et al.* 2014, Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. *Academic Radiology*, vol.21(10): 1255–1261.

112. Eagan T M L, Aukrust P, Ueland T, *et al.* 2010, Body composition and plasma levels of inflammatory biomarkers in COPD. *European Respiratory Journal*, vol.36(5): 1027–1033.

113. Husebo G R, Bakke P S, Aanerud M, *et al.* 2014, Predictors of exacerbations in chronic obstructive pulmonary disease — results from the Bergen COPD cohort study. *PloS One*, vol.9(10): e109721.

114. Janssen D J A, Muellerova H, Agusti A, *et al.* 2014, Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. *Respiratory Medicine*, vol.108(11): 1647–1654.

115. Singh D, Edwards L, Tal-Singer R, *et al.* 2010, Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. *Respiratory Research*, vol.11: 77.

116. Mannino D M, Tal-Singer R, Lomas D A, *et al.* 2015, Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, vol.2(1): 23–34.

117. Eagan T M, Aukrust P, Bakke P S, *et al.* 2010, Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease. *Respiratory Medicine*, vol.104(2): 283–290.

118. Eagan T M, Damas J K, Ueland T, *et al.* 2010, Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. *Chest*, vol.138(4): 888–895.

119. Kunisaki K M, Niewoehner D E, Connett J E, *et al.* 2012, Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. *American Journal of Respiratory and Critical Care Medicine*, vol.185(3): 286–290.